OncoMatch/Clinical Trials/NCT05504265

Perioperative Analgesia Modes in Minimally Invasive Esophagectomy

Is NCT05504265 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Preemptive flurbiprofen axetil and Postoperative flurbiprofen axetil for esophageal cancer.

Phase 2/3RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05504265Data as of May 2026

Treatment: Preemptive flurbiprofen axetil · Postoperative flurbiprofen axetil — This study was designed to compare analgesic efficacy and safety of different perioperative analgesic modes in minimally invasive esophagectomy for esophageal cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Lab requirements

Cardiac function

Preoperative cardiac function grade ≥ III or coronary artery stenosis [excluded]

Preoperative cardiac function grade ≥ III or coronary artery stenosis

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify